Cargando…

Pharmacotherapy Evaluation and Utilization in Coronary Artery Bypass Grafting Patients in Kosovo during the Period 2016-2017

BACKGROUND: Coronary Artery Bypass Grafting (CABG) is realised in patients with critical or advanced disease of coronary arteries. There are different pharmacotherapeutic approaches which are used as management, treatment and preventive therapy in cardiovascular disease or related comorbidities. Per...

Descripción completa

Detalles Bibliográficos
Autores principales: Daci, Armond, Bozalija, Adnan, Cavolli, Raif, Alaj, Rame, Beretta, Giangiacomo, Krasniqi, Shaip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Republic of Macedonia 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874373/
https://www.ncbi.nlm.nih.gov/pubmed/29610608
http://dx.doi.org/10.3889/oamjms.2018.132
_version_ 1783310154259759104
author Daci, Armond
Bozalija, Adnan
Cavolli, Raif
Alaj, Rame
Beretta, Giangiacomo
Krasniqi, Shaip
author_facet Daci, Armond
Bozalija, Adnan
Cavolli, Raif
Alaj, Rame
Beretta, Giangiacomo
Krasniqi, Shaip
author_sort Daci, Armond
collection PubMed
description BACKGROUND: Coronary Artery Bypass Grafting (CABG) is realised in patients with critical or advanced disease of coronary arteries. There are different pharmacotherapeutic approaches which are used as management, treatment and preventive therapy in cardiovascular disease or related comorbidities. Performing a successful surgery, pharmacotherapy, and increase of bypass patency rate remains a serious challenge. AIM: This study aims to analyse the patient characteristics undergoing CABG and evaluation of their drug utilisation rate and daily dosages in the perioperative period. MATERIAL AND METHODS: Data were collected from 102 patients in the period 2016-2017 and detailed therapeutic prescription and dosages, patient characteristics were analysed before the operation, after the operation and visit after operation in the Clinic of Cardiac surgery-University Clinical Center of Kosovo. RESULTS: Our findings had shown that patients provided to have normal biochemical parameters in the clinic before the operation, and were related to cardiovascular diseases and comorbidities and risk factors with mainly elective intervention. The, however, higher utilisation of cardiovascular drugs such as beta blockers, diuretics, anticoagulants, statins and lower calcium blockers, ACEi, ARBs, hydrochlorothiazide, amiodarone were founded. ARBs, beta blockers, statins, nitrates and nadroparin utilisation decreased after operation and visit after the operation, whereas amiodarone only in the visit after the operation. Diuretics are increased after the operation which decreases in the visit after the operation. Regarding the daily dosage, only metoprolol was increased in the visit after operation (P < 0.001) and visit after operation (P < 0.05) whereas losartan and furosemide were increased (P < 0.01) and (P < 0.05) respectively. CONCLUSION: The study showed that beta blockers, statins, aspirin, nitrates (before the operation), furosemide and spironolactone are the most utilised drugs. However, we found low utilisation rate for ACEi, ARBs, clopidogrel, nadroparin, warfarin, xanthines, amiodarone, calcium blockers. Daily dosages were different compared to before CABG only in metoprolol, losartan, and furosemide.
format Online
Article
Text
id pubmed-5874373
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Republic of Macedonia
record_format MEDLINE/PubMed
spelling pubmed-58743732018-04-02 Pharmacotherapy Evaluation and Utilization in Coronary Artery Bypass Grafting Patients in Kosovo during the Period 2016-2017 Daci, Armond Bozalija, Adnan Cavolli, Raif Alaj, Rame Beretta, Giangiacomo Krasniqi, Shaip Open Access Maced J Med Sci Clinical Science BACKGROUND: Coronary Artery Bypass Grafting (CABG) is realised in patients with critical or advanced disease of coronary arteries. There are different pharmacotherapeutic approaches which are used as management, treatment and preventive therapy in cardiovascular disease or related comorbidities. Performing a successful surgery, pharmacotherapy, and increase of bypass patency rate remains a serious challenge. AIM: This study aims to analyse the patient characteristics undergoing CABG and evaluation of their drug utilisation rate and daily dosages in the perioperative period. MATERIAL AND METHODS: Data were collected from 102 patients in the period 2016-2017 and detailed therapeutic prescription and dosages, patient characteristics were analysed before the operation, after the operation and visit after operation in the Clinic of Cardiac surgery-University Clinical Center of Kosovo. RESULTS: Our findings had shown that patients provided to have normal biochemical parameters in the clinic before the operation, and were related to cardiovascular diseases and comorbidities and risk factors with mainly elective intervention. The, however, higher utilisation of cardiovascular drugs such as beta blockers, diuretics, anticoagulants, statins and lower calcium blockers, ACEi, ARBs, hydrochlorothiazide, amiodarone were founded. ARBs, beta blockers, statins, nitrates and nadroparin utilisation decreased after operation and visit after the operation, whereas amiodarone only in the visit after the operation. Diuretics are increased after the operation which decreases in the visit after the operation. Regarding the daily dosage, only metoprolol was increased in the visit after operation (P < 0.001) and visit after operation (P < 0.05) whereas losartan and furosemide were increased (P < 0.01) and (P < 0.05) respectively. CONCLUSION: The study showed that beta blockers, statins, aspirin, nitrates (before the operation), furosemide and spironolactone are the most utilised drugs. However, we found low utilisation rate for ACEi, ARBs, clopidogrel, nadroparin, warfarin, xanthines, amiodarone, calcium blockers. Daily dosages were different compared to before CABG only in metoprolol, losartan, and furosemide. Republic of Macedonia 2018-03-12 /pmc/articles/PMC5874373/ /pubmed/29610608 http://dx.doi.org/10.3889/oamjms.2018.132 Text en Copyright: © 2018 Armond Daci, Adnan Bozalija, Raif Cavolli, Rame Alaj, Giangiacomo Beretta, Shaip Krasniqi. http://creativecommons.org/licenses/CC BY-NC/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
spellingShingle Clinical Science
Daci, Armond
Bozalija, Adnan
Cavolli, Raif
Alaj, Rame
Beretta, Giangiacomo
Krasniqi, Shaip
Pharmacotherapy Evaluation and Utilization in Coronary Artery Bypass Grafting Patients in Kosovo during the Period 2016-2017
title Pharmacotherapy Evaluation and Utilization in Coronary Artery Bypass Grafting Patients in Kosovo during the Period 2016-2017
title_full Pharmacotherapy Evaluation and Utilization in Coronary Artery Bypass Grafting Patients in Kosovo during the Period 2016-2017
title_fullStr Pharmacotherapy Evaluation and Utilization in Coronary Artery Bypass Grafting Patients in Kosovo during the Period 2016-2017
title_full_unstemmed Pharmacotherapy Evaluation and Utilization in Coronary Artery Bypass Grafting Patients in Kosovo during the Period 2016-2017
title_short Pharmacotherapy Evaluation and Utilization in Coronary Artery Bypass Grafting Patients in Kosovo during the Period 2016-2017
title_sort pharmacotherapy evaluation and utilization in coronary artery bypass grafting patients in kosovo during the period 2016-2017
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874373/
https://www.ncbi.nlm.nih.gov/pubmed/29610608
http://dx.doi.org/10.3889/oamjms.2018.132
work_keys_str_mv AT daciarmond pharmacotherapyevaluationandutilizationincoronaryarterybypassgraftingpatientsinkosovoduringtheperiod20162017
AT bozalijaadnan pharmacotherapyevaluationandutilizationincoronaryarterybypassgraftingpatientsinkosovoduringtheperiod20162017
AT cavolliraif pharmacotherapyevaluationandutilizationincoronaryarterybypassgraftingpatientsinkosovoduringtheperiod20162017
AT alajrame pharmacotherapyevaluationandutilizationincoronaryarterybypassgraftingpatientsinkosovoduringtheperiod20162017
AT berettagiangiacomo pharmacotherapyevaluationandutilizationincoronaryarterybypassgraftingpatientsinkosovoduringtheperiod20162017
AT krasniqishaip pharmacotherapyevaluationandutilizationincoronaryarterybypassgraftingpatientsinkosovoduringtheperiod20162017